Catalog # HM2111F
C9, Human, mAb X197, FITC
Please choose the quantity of items you wish to add to your cart…
Find distributor Human C9 is a soluble glycoprotein of 61 kD. It is the last component in the assembly of the membrane attack complex (MAC). When the complement is activated on target membranes, multiple copies of C9 bind to the C5b-8 complex and assemble the barrel-shaped pore which causes cell lysis. The conformation of C9 changes from globular to a tubular form. The binding of C9 to C5b-8 plays a key role in the function of C9.
Application
Flow cytometry, Frozen sections, Immuno assays, Paraffin sections, Western blot
Use
For immunohistology, flow cytometry and Western blotting dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:10.
Product type
Monoclonal antibodies
Amount
100 µg, 20 µg
Formulation
0.2 ml (100 µg/ml) 0.2 µm filtered FITC conjugated antibody solution in PBS, containing 1% bovine serum albumin and 0.02% sodium azide
Conjugate
FITC
Isotype
Mouse IgG1
Species
Human
Storage and stability
Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
Precautions
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use of or derivation of this product.
Disease
Infectious diseases, Nephrology
Protocol
CoA-TDS HM2100-HM2199
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA